Subscribe
Share
Share
Embed
A short preview of this episode.
A short preview of this episode.
Ever wonder why some people feel unstoppable while others struggle with the same health issues? Every week, our functional medicine professionals spill the secrets:
Jaw-dropping patient success stories
Root cause reports your doctor might have missed
Life-changing tips & insider tricks.
The Med Matrix Method is created to help you finally take control of your health. Tune in and start living your most optimal life—your body will thank you.
But what happens when a therapy becomes popular with patients before the medical system fully agrees on how to regulate it? That is the center of the BPC-157 debate. BPC-157 has become one of the most talked about peptides in functional medicine and regenerative health with patients asking about it for gut health, tissue repair, inflammation, injury recovery, and healing. At the same time, the FDA has raised concerns about compounded peptides, limited human safety data, quality control, and whether access is moving faster than the evidence. This conversation is especially relevant right now. Last month, in July of 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed several peptides, including BPC-157-related bulk drug substances, for potential inclusion on the 503A bulks list. FDA's own meeting agenda listed BPC-157 as being evaluated for ulcerative colitis, while recent reporting noted that FDA advisors recommended a broader access to six out of seven peptides reviewed. Even as FDA staff continued to raise concerns about limited safety and effectiveness data. In this episode of the MedMatrix Method, we're breaking down the BPC-157 battle. What patients are hearing online, what the evidence actually says, what the FDA is concerned about, and how functional medicine can approach peptide therapy without turning it into hype.